Aktienanalyse zu Vanda Pharmaceuticals Inc (VNDA)VNDAVanda Pharmaceuticals Inc

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company, which is focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company's commercial portfolio consist of four products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome, PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS) including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease , and NEREUS for the prevention of vomiting induced by motion. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Vanda Pharmaceuticals Inc is currently priced at $3.88, which is significantly below its 52-week high of $9.94, indicating potential upside. However, the stock has a low RSI of 35.207, suggesting it is oversold, but the forward P/E ratio is high at 103.09, indicating that the stock may be overvalued based on future earnings expectations. The recent insider selling has increased by 972.59%, which raises concerns about the company's outlook. Therefore, while there is potential for recovery, the risks associated with high valuation and insider selling suggest a hold position for now.

6 analysts cover VNDA: 5 rate it Buy, 0 Hold and 1 Sell. The average price target is 13.63.